Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Desidustat in Chemotherapy-Induced Anemia
NCT04667533Phase 1Completed
- Sponsor
- Zydus Lifesciences Limited
- Start
- Nov 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of desidustat (3 arms), sponsored by Zydus Lifesciences Limited. Primary endpoint: Adverse events at Day 30. Started Nov 2020; status: completed.
02
Drugs
desidustat
Beyond the preview
Go deeper on NCT04667533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04667533.